Supporting Therapy Platform Development With Advanced Characterization Of Engineered T Cells Via Single-cell Sequencing And Flow Cytometry

By Christina Codden, Scientist II, Bioinformatics

This poster showcases an integrated analytical framework combining single‑cell sequencing and flow cytometry to deeply characterize engineered T‑cell therapy products. The approach resolves cellular heterogeneity, measures on‑target editing, and detects rare off‑target events at per‑cell resolution while linking these molecular footprints to functional phenotypes measured by immunophenotyping. By coupling high‑dimensional sequencing readouts with standardized cytometric profiles, the workflow identifies critical quality attributes, informs potency and safety assessments, and supports iterative optimization of therapy platforms—especially in settings where bulk methods can obscure minor but clinically relevant subpopulations. The work reflects a broader trend: single‑cell multi‑omics delivers the granularity required to evaluate product composition and potential genotoxicity, complementing established immunoassays used in manufacturing and release testing. Together, these techniques provide actionable insights to accelerate development of robust, reproducible engineered T‑cell therapies and help advance precision strategies for complex, living drug products.